ABSTRACT
BACKGROUND: Urinary incontinence (UI), erectile dysfunction and cardiometabolic conditions are common after prostatectomy for prostate cancer (PCa). Although physical activity could improve overall survival and quality of survivorship, fear of UI can restrict participation in exercise. Individuals with PCa could benefit from therapeutic exercise programming to support continence recovery and cardiometabolic health. AIM: The main objective of this study is to determine the feasibility and the effects of a combined pelvic health rehabilitation and exercise fitness program on UI after prostatectomy. The combined exercise program will be delivered both in-person and virtually. METHODS: This study follows a modified Zelen, two-arm parallel randomized controlled trial design. A total of 106 individuals with PCa will be recruited before prostatectomy surgery. Participants will be randomized between two groups: one receiving usual care and one receiving a combined exercise fitness and intensive pelvic floor muscle training program. Exercise programming will begin 6-8 weeks after prostatectomy and will last 12 weeks. Outcomes include: the 24-h pad test (primary outcome for UI); physical fitness, metabolic indicators, and patient-reported outcomes on erectile function, self-efficacy, severity of cancer symptoms and quality of life. Important timepoints for assessments include before surgery (T0), after surgery (T1), after intervention (T3) and at one-year after surgery (T4). CONCLUSION: This study will inform the feasibility of offering comprehensive exercise programming that has the potential to positively impact urinary continence, erectile function and cardiometabolic health of individuals undergoing prostatectomy for prostate cancer. CLINICALTRIALS REGISTRATION NUMBER: NCT06072911.
Subject(s)
Cardiovascular Diseases , Erectile Dysfunction , Prostatic Neoplasms , Urinary Incontinence , Male , Humans , Erectile Dysfunction/etiology , Erectile Dysfunction/rehabilitation , Quality of Life , Feasibility Studies , Pelvic Floor , Exercise Therapy/methods , Urinary Incontinence/etiology , Urinary Incontinence/surgery , Prostatectomy/methods , Prostatic Neoplasms/surgery , Exercise , Treatment Outcome , Randomized Controlled Trials as TopicABSTRACT
INTRODUCTION: A variety of procedures for the endoscopic surgical treatment of symptomatic benign prostatic hyperplasia (BPH) refractory to medical therapy have existed for decades. The present study examined trends in surgeon compensation for these treatments within Canada. METHODS: The physician fee schedule for BPH surgery across 10 Canadian provinces for the years 2010 and 2023 were obtained. A descriptive study examined first the provincial reimbursement for transurethral resection of prostate (TURP) and laser ablative/enucleation surgery; second, the difference in TURP reimbursement between 2010 and 2023; and third, the annual change in TURP reimbursement juxtaposed with the annual change in the provincial Consumer Price Index (CPI) and annual salary for the working population aged 35-44. RESULTS: Seven of 10 Canadian provinces reimburse laser BPH surgery equally to TURP. The average provincial TURP reimbursement is $545, ranging from $451 in Ontario to $688 in Saskatchewan. Since 2010, TURP reimbursement has varied by province from a 0% net change in Ontario to an increase of 21% in Nova Scotia. Reimbursement for TURP has increased at a slower pace than the local CPI, and for half of the provinces at a slower pace than the annual salary for people aged 35-44. CONCLUSIONS: The compensation model for endoscopic BPH surgery does not have a unified structure in Canada that is consistent across provinces, nor does it keep up with inflation, possibly impacting future recruitment, increasing geographic disparities, and most importantly, limiting the adoption of new BPH therapies.
ABSTRACT
Importance: Prostate-specific membrane antigen (PSMA) demonstrates overexpression in prostate cancer and correlates with tumor aggressiveness. PSMA positron emission tomography (PET) is superior to conventional imaging for the metastatic staging of prostate cancer per current research but studies of second-generation PSMA PET radioligands for locoregional staging are limited. Objective: To determine the accuracy of fluorine-18 PSMA-1007 PET/computed tomography (18F-PSMA-1007 PET/CT) compared to multiparametric magnetic resonance imaging (MRI) in the primary locoregional staging of intermediate-risk and high-risk prostate cancers. Design, Setting, and Participants: The Next Generation Trial was a phase 2 prospective validating paired cohort study assessing the accuracy of 18F-PSMA-1007 PET/CT and MRI for locoregional staging of prostate cancer, with results of histopathologic examination as the reference standard comparator. Radiologists, nuclear medicine physicians, and pathologists were blinded to preoperative clinical, pathology, and imaging data. Patients underwent all imaging studies and radical prostatectomies at 2 tertiary care hospitals in Alberta, Canada. Eligible participants included men with intermediate-risk or high-risk prostate cancer who consented to radical prostatectomy. Participants who underwent radical prostatectomy were included in the final analysis. Patients were recruited between March 2022 and June 2023, and data analysis occurred between July 2023 and December 2023. Exposures: All participants underwent both 18F-PSMA-1007 PET/CT and MRI within 2 weeks of one another and before radical prostatectomy. Main Outcomes and Measures: The primary outcome was the correct identification of the prostate cancer tumor stage by each imaging test. The secondary outcomes were correct identification of the dominant nodule, laterality, extracapsular extension, and seminal vesical invasion. Results: Of 150 eligible men with prostate cancer, 134 patients ultimately underwent radical prostatectomy (mean [SD] age at prostatectomy, 62.0 [5.7] years). PSMA PET was superior to MRI for the accurate identification of the final pathological tumor stage (61 [45%] vs 38 [28%]; P = .003). PSMA PET was also superior to MRI for the correct identification of the dominant nodule (126 [94%] vs 112 [83%]; P = .01), laterality (86 [64%] vs 60 [44%]; P = .001), and extracapsular extension (100 [75%] vs 84 [63%]; P = .01), but not for seminal vesicle invasion (122 [91%] vs 115 [85%]; P = .07). Conclusions and Relevance: In this phase 2 prospective validating paired cohort study, 18F-PSMA-1007 PET/CT was superior to MRI for the locoregional staging of prostate cancer. These findings support PSMA PET in the preoperative workflow of intermediate-risk and high-risk tumors.
Subject(s)
Fluorine Radioisotopes , Multiparametric Magnetic Resonance Imaging , Neoplasm Staging , Positron Emission Tomography Computed Tomography , Prostatic Neoplasms , Humans , Male , Positron Emission Tomography Computed Tomography/methods , Prostatic Neoplasms/diagnostic imaging , Prostatic Neoplasms/pathology , Prostatic Neoplasms/surgery , Multiparametric Magnetic Resonance Imaging/methods , Middle Aged , Aged , Prospective Studies , Radiopharmaceuticals , Niacinamide/analogs & derivatives , Oligopeptides , Glutamate Carboxypeptidase II/metabolism , Antigens, Surface/metabolismABSTRACT
As presas de 132 espécies de vespas Bembicini (Hymenoptera) que foram estudadas são revisadas. Cerca de três quartos das espécies predam Diptera e acredita-se que a predação de moscas é um evento ancestral no grupo. Onze espécies predam, além de Diptera, ocasionalmente ou regularmente espécies de Lepidoptera, Hymenoptera, Neuroptera, Odonata e/ou Homoptera. Entretanto, outras 21 espécies pertencentes a cinco gêneros predam espécies das cinco ordens mencionadas, mas não predam Diptera. Especula-se que esse fato represente uma progressão evolucionária, quando populações de vespídeos foram expostas à escassez de dípteros no passado e foram obrigadas a ampliar o foco incluindo presas pertencentes a outros grupos de insetos voadores. Esse comportamento inicialmente aprendido foi revigorado geneticamente ao longo do tempo evolucionário para produzir a radiação atual no número de presas dentro do grupo.
The prey of 132 species of Bembicini (Hymenoptera) that have been studied is reviewed. About three quarters of the species prey on Diptera, and it is believed that fly predation is ancestral in the group. Eleven species make occasional or regular use of other insects as prey in addition to Diptera (Lepidoptera, Hymenoptera, Neuroptera, Odonata, and/or Homoptera), while 21 species of five genera prey on insects of these same five groups with no use of Diptera. It is hypothesized that this represents an evolutionary progression, whereby populations have experienced shortages of dipterous prey in the past and have broadened their sensory focusing to include other groups of flying insects. Behavior initially learned has, over time, been reinforced genetically to produce the currently observed radiation in prey choice within the group.